MIRUM PHARMACEUTICALS INC (MIRM) Stock Price, Quote, News and Overview
NASDAQ:MIRM - Nasdaq - US6047491013 - Common Stock
MIRM Quote and Key Statistics
MIRUM PHARMACEUTICALS INC
NASDAQ:MIRM (1/21/2025, 8:14:20 PM)
After market: 50.37 +2.39 (+4.98%)47.98
+1.03 (+2.19%)
MIRM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.94% | ||
| ROE | -43.02% | ||
| Debt/Equity | 1.33 |
MIRM Performance and Technical Analysis
MIRM Ownership and Analysts
MIRM Latest News and Analysis
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
About MIRM
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 311 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Company Info
MIRUM PHARMACEUTICALS INC
989 East Hillsdale Boulevard, Suite 300
Foster City CALIFORNIA 94404 US
CEO: Christopher Peetz
Employees: 294
Company Website: https://mirumpharma.com/
Investor Relations: https://ir.mirumpharma.com/
Phone: 16506674085
MIRM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |